Hossein Amirani, MD
Cardiovascular Disease · Wichita, KSNPI 1164493201
Payments from drug & device makers
Across 378 payments — averaging $47.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Medtronic$6K
- AstraZeneca$752
- Organogenesis Inc.$527
- Cvrx, Inc.$423
- Philips North America LLC$408
- plus $3K from 33 others
What the payments were for
- Travel & lodging$5,07828%
- Food & beverage$12,14568%
- Education$6934%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 99 | $6,371 |
| Medtronic(2 entities) | 65 | $6,016 |
| AstraZeneca | 29 | $752 |
| Organogenesis Inc. | 9 | $527 |
| Cvrx, Inc. | 7 | $423 |
| Philips North America LLC | 10 | $408 |
| Amgen | 24 | $400 |
| Boehringer Ingelheim | 20 | $325 |
| Novo Nordisk | 18 | $321 |
| Johnson & Johnson | 14 | $283 |
| Merck | 11 | $246 |
| Pfizer | 14 | $239 |
| Novartis | 7 | $167 |
| Edwards Lifesciences | 1 | $166 |
| Abiomed | 2 | $127 |
| Bard Peripheral Vascular, Inc. | 2 | $120 |
| Intuitive Surgical | 1 | $118 |
| Esperion Therapeutics, Inc. | 3 | $115 |
| Endologix LLC | 1 | $101 |
| Amarin Pharma, Inc. | 6 | $93 |
| Bardy Diagnostics, Inc. | 5 | $79 |
| Kestra Medical Technology Services, Inc. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Bayer | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Boston Scientific | 2 | $38 |
| Lundbeck LLC | 2 | $27 |
| Shockwave Medical, Inc | 1 | $25 |
| Gilead | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Cardinal Health 200 LLC | 1 | $20 |
| Elutia, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $13 |
| Cordis US CORP. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$2,966
- AVEIR$2,915
- Confirm Rx$359
- CardioMEMS HF System$282
- Barostim Neo System$247
- Edwards SAPIEN 3 Transcatheter Heart Valve$166
- MitraClip System$146
- Durata Defibrillation ICD Lead$141
- NuShield$136
- PRESSUREWIRE$135
- ALLURE QUADRA$123
- Da Vinci Surgical System$118
- Quadra Assura CRT Defibrillator$117
- XARELTO$115
- ESPRIT$115
- ASSURITY$113
- Impella$111
- CARDIOMEMS$107
- Cobalt$105
- IGT D Peripheral$103
How this compares
$17,917 in reported general payments places this provider in the 85th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,455 | $1,932,455 |
| XareltoRivaroxaban | 1,261 | $1,206,221 |
| EntrestoSacubitril/Valsartan | 462 | $433,387 |
| FarxigaDapagliflozin Propanediol | 444 | $388,298 |
| JardianceEmpagliflozin | 350 | $263,459 |
| Repatha SureclickEvolocumab | 302 | $220,863 |
| MultaqDronedarone Hcl | 141 | $128,165 |
| BrilintaTicagrelor | 174 | $105,221 |
| WegovySemaglutide | 32 | $41,885 |
| OzempicSemaglutide | 18 | $16,669 |
| Praluent PenAlirocumab | 29 | $14,271 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 65 | $13,555 |
| Atorvastatin Calcium | 2,389 | $13,390 |
| LivaloPitavastatin Calcium | 31 | $12,593 |
| VascepaIcosapent Ethyl | 16 | $11,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $239 | $1,932,4552,455 claims |
| Johnson & JohnsonXarelto | $283 | $1,206,2211,261 claims |
| AstraZenecaFarxiga, Brilinta | $752 | $493,519618 claims |
| NovartisEntresto | $167 | $433,387462 claims |
| Boehringer IngelheimJardiance, Pradaxa | $325 | $266,178362 claims |
| Sanofi-aventis U.S. LLCMultaq | $41 | $128,165141 claims |
| Novo NordiskWegovy, Ozempic | $321 | $58,55450 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $15 | $12,59331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Thomas AshcomWichita$193K
- Joseph GalichiaWichita$177K
- Layne ReusserWichita$91K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.